Clinical Study
Denosumab for Male Hemodialysis Patients with Low Bone Mineral Density: A Case-Control Study
| (a) Mean medication dose in the treatment course of the denosumab group |
| | | Baseline | 3 months | 6 months | 12 months |
| | CaCo3 (g/day) | 1.47 (15) | 1.65 (16) | 1.18 (15) | 1.32 (15) | | Alfacalcidol (μg/day) | 0.31 (11) | 0.43 (11) | 0.34 (10) | 0.34 (11) | | Calcitriol (μg/day) | 0.01 (1) | 0.03 (1) | 0.03 (1) | 0 (0) | | Maxacalcitol (μg/week) | 5.0 (2) | 4.41 (2) | 2.94 (2) | 4.71 (3) | | Cinacalcet (mg/day) | 2.94 (8) | 2.94 (10) | 2.94 (8) | 4.41 (9) |
|
|
The number in the parentheses denotes the number of patients treated with each medication among the 17 patients.
|
| (b) Mean medication dose in the treatment course in the control group |
| | | Baseline | 3 months | 6 months | 12 months |
| | CaCo3 (g/day) | 1.50 (14) | 1.73 (15) | 1.10 (15) | 1.6 (15) | | Alfacalcidol (μg/day) | 0.03 (2) | 0.01 (1) | 0.01 (1) | 0.01 (1) | | Calcitriol (μg/day) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | | Maxacalcitol (μg/week) | 10.0 (7) | 8.75 (7) | 10.0 (6) | 10.0 (14) | | Cinacalcet (mg/day) | 6.75 (16) | 11.25 (17) | 7.50 (17) | 11.25 (17) |
|
|
The number in the parentheses denotes the number of patients treated with each medication among the 20 patients.
|
